MichelleRengarajanMD

Internal Medicine • Boston, MA

Endocrinology

Fellow at Massachusetts General Hospital

Join to view full profile

Dr. Rengarajan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rengarajan's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-726-3872

Fax+1 617-726-5905

Education & Training

Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2018 - 2022
Brigham and Women's HospitalResidency, Internal Medicine, 2016 - 2018
Stanford University School of MedicineClass of 2016

Certifications & Licensure

MA State Medical License 2016 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Publications & Presentations

PubMed

1 citations
Identification of Immune Checkpoint Inhibitor-Induced Diabetes.
Karina N Ruiz-Esteves, Kaitlyn R Shank, Aaron J Deutsch, Alekhya Gunturi, Natalia Chamorro-Pareja
JAMA Oncology. 2024-10-01
1 citations
Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.
Jonathan R Wing, Allison Kimball, Michelle Rengarajan
The New England Journal of Medicine. 2022-02-24
15 citations
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer.
Leyre Zubiri, Gabriel E. Molina, Meghan J. Mooradian, Justine V. Cohen, Sienna Durbin
Journal for Immunotherapy of Cancer. 2021-09-01

Press Mentions

Identification of Immune Checkpoint Inhibitor–Induced DiabetesAugust 29th, 2024